Strongbridge Biopharma:Are There Further Upsides To This Stellar Grower?
Data for the phase 3 trials (SONICS and LOGICS) studying COR-003 (Recorlev) as the treatment for Cushing’s syndrome will be posted this year.
Recorlev has the edge to capture the Cushing’s syndrome market (and to most likely generate significant sales).
Company strategically issued 5M shares to strengthen the capital position for its pipeline innovation.
I had made what I believe was one of the more valuable decisions of my business life. This was to confine all efforts solely to making major gains in the long-run. The Father of Growth Investing (Philip Fisher)
In the past 52-weeks, the shares of Strongbridge Biopharma (NASDAQ:SBBP) – a bioscience firm, focusing on the development and commercialization of therapeutics to service the rare diseases market – traded $6.2 higher at $8.70 (for 248% total profits). Like many stocks that we recommended to our partners, there are key catalysts powering Strongbridge. All that being said, the elephant in the room is whether there are further upsides to this firm. In this report, we’ll elucidate the substantial unlocked value of Strongbridge (and assess various unlocked catalysts that can catapult the share price to new highs).